If corticosteroid nasal sprays are used in high doses for long periods of time, they do have the potential to cause side effects similar to those associated with corticosteroids taken by mouth, such as cataracts, raised pressure in the eye or glaucoma, Cushing's syndrome, adrenal suppression and mental health problems. However, these types of side effect are extremely unlikely to occur with this nasal spray, because the amount of budesonide absorbed into the bloodstream from the nose is very low. As a precaution, always use the lowest effective dose needed to control your symptoms, and for the shortest possible time.

In animal reproduction studies, corticosteroids such as budesonide have been shown to induce malformations (cleft palate, skeletal malformations). However, these animal experimental results do not appear to be relevant in humans at the recommended doses. The application contained a risk management plan ( RMP). RMPs contain information on a medicine’s safety profile and one or more of the following: Paediatric population: This medicine should not be used in children and adolescents under 18 years of age. Also ask your doctor or pharmacist's advice if you feel better before 7 days but are not sure if you can stop.

Advice for patients that they should use the lowest dose at which effective control of symptoms is achieved If symptoms persist or are not adequately controlled after 7 days of treatment patients should consult their doctor or pharmacist. This medicine should not be used continuously for longer than 1 month without seeking medical advice. Paediatric population: This spray should not be used in children and adolescents under 18 years of age. Pharmacotherapeutic group: Decongestants and other nasal preparations for topical use, corticosteroids. ATC code: R01A D05 Budesonide nasal spray is available on prescription for adults and children aged 6 years old and over. You can also buy it from pharmacies and shops for adults aged 18 years old and over.

At The Independent Pharmacy, we offer a range of hay fever and allergy treatments. This includes an alternative corticosteroid and antihistamine nasal sprays, antihistamine tablets, liquid solutions and eye drops designed to relieve hay fever symptoms that affect the eyes and nose as well as the rest of the body. Patients should consult a pharmacist or doctor if they develop signs or symptoms of an infection, such as persistent fever, while taking this medicine. If you are using the spray for hay fever, your doctor may recommend that you start using it 2-3 weeks before the hay fever season starts. This is because it takes a few days of treatment before you feel the full effect, so starting before the pollen count rises will help to prevent symptoms from developing. The RMP for this product considered the main risks associated with the product and proposed additional warnings on the labelling and PIL about the symptoms which a patient should seek further advice from a doctor or pharmacist. The MHRA considers that apart from this, no further risk minimisation measures are need for this application. 6. Reasons for not seeking advice from the Commission on Human Medicines BENADRYL ® products contain the following active ingredients: BENADRYL ® Allergy One A Day 10mg tablets & BENADRYL ® Allergy Children’s 1mg/ml Oral Solution (2+years) & BENADRYL ® Allergy Children’s 6+ 1mg/ml Oral Solution - Cetirizine (antihistamine); BENADRYL ® Allergy Relief Plus Decongestant Capsules - acrivastine (antihistamine) & Pseudoephedrine (decongestant); BENADRYL ® Allergy Relief Capsules – acrivastine (antihistamine); BENADRYL ® Allergy Natural Relief Nasal Spray (from birth) is a medical device; BENACORT ® 64 micrograms Nasal Spray and BENACORT ® Hayfever Relief for Adults 64 micrograms, nasal spray contain budesonide

It can take up to a couple of days before the full effects of Benacort Nasal Spray can be felt, but with regular use, the relief this medicine offers is significant and long-lasting. These can be signs of a serious allergic reaction and may need immediate treatment in hospital. Other side effects Benacort Nasal Spray Patient Information Leaflet: https://www.medicines.org.uk/emc/files/pil.10205.pdf Allergic reactions such as rash, itching, hives or swelling of the face or tongue. Stop using Benacort and get medical advice if you think you've had an allergic reaction to it. The summary of product characteristics includes the interaction of Benacort Hayfever Relief with several medicines. If a patient is on any of the medicines that interact with Benacort Hayfever Relief, patients are alerted to the interaction on the label and patient information leaflet ( PIL).

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines that you buy without a prescription and herbal medicines. This is because Benacort® Hayfever Relief can affect the way some medicines work, and some medicines can have an effect on Benacort® Hayfever Relief. So, your doctor may wish to monitor you carefully. In particular talk to your doctor or pharmacist if: Maintenance treatment with inhaled budesonide (200 or 400 micrograms twice daily) in asthmatic nursing women results in negligible systemic exposure to budesonide in breast-fed infants. The maximal duration of treatment is 1 month’s continuous self-care use, before seeking medical advice. The full name of the medicine is Benacort Hayfever Relief for Adults 64 micrograms, nasal spray. In this document, we will call it ‘Benacort Hayfever Relief’. Plans for studies and other activities to gain more knowledge about the safety and efficacy of the medicine

Piriteze Allergy Tablets - 30 Tablets

you're breathing very fast or struggling to breathe (you may become very wheezy or feel like you're choking or gasping for air) Talk to your pharmacist or doctor if you get any of the following while using Benacort® Hayfever Relief: Benacort® Hayfever Relief is manufactured by McNeil AB, Norrbroplatsen 2, 251 09, Helsingborg, Sweden. Budesonide is distributed widely into tissues with plasma protein binding averaging between 85 and 90%. The epimers of budesonide have large volumes of distribution – 424 L for 22R-budesonide and 245 L for 22S budesonide. 22R- budesonide has a larger volume of distribution than the 22S epimer due to its greater lipophilicity. At steady state, the active, unbound form of budesonide has a volume of distribution of approximately 3 L/kg in both adults and children.